Antigen Presentation and Lymphocyte Response in Parkinson's Disease

Columbia University

Status: Completed

Conditions: Parkinson's Disease

Study type: Observational

Funder types: Other

Identifiers

NCT02939534

AAAN7912

Details and patient eligibility

About

The way the immune system responds to certain PD-related proteins in PD donors compared to the way it responds in persons without or fewer PD related proteins is not well studied and this study aims to analyze the autoimmune response in each group. The study involves a one time visit involving brief questionnaires and a blood draw of 30 mL (approximately 2 tablespoons) to be collected.

Full description

The role of the immune response in Parkinson's disease (PD) is controversial. Recent studies show that neurons can present MHC-I (major histocompatibility complex - class 1) molecules and therefore may be susceptible to an attack by immune cells. The investigators anticipate that the results of this study will improve our understanding of the mechanisms of immune mediated neuronal degeneration in PD. Initial results suggest that antigens are presented by neuronal MHC-I in PD, and that this could lead to T-cell mediated neuronal death. The most obvious antigen that could be differentially expressed in PD patients and controls would be alpha-synuclein (-syn): -syn oligomers appear in all Lewy bodies and Lewy neurites and are the hallmark of PD changes in the brain. This study will offer the opportunity to further characterize the immune mediated component of PD, and to continue elucidating the biology that underlies antigen presentation and T-cell cytolytic activity.

Enrollment: 95 patients

Sex: All

Ages: 50 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Moderate to advanced PD with classic motor features, and must demonstrate two of the following three: rest tremor, rigidity, or bradykinesia
• Dopaminergic medication benefit (self-reported improvement)
• Age at recruitment: 50 - 90 years
• Age at diagnosis > 47
• PD duration > 3 years
• Willingness to have genotyping and genetic studies as part of laboratory research

Exclusion criteria

• Atypical parkinsonism or other neurological disorders
• Recent history of cancer (past 3 years)
• Autoimmune disease (except thyroid disease)
• On chronic immune-modulatory therapy (e.g. SIT (specific immunotherapy), anti-IgE)
• Inability to provide informed consent

Trial design

95 participants in 1 patient group

PD and Controls

Description:

50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease